Literature DB >> 4348470

Neuraminidase induced loss in the transplantability of murine leukaemia L 1210, induction of immunoprotection and the transfer of induced immunity to normal DBA-2 mice by serum and peritoneal cells.

K K Sethi, H Brandis.   

Abstract

Leukaemia L 1210 cells preincubated in vitro with neuraminidase preparations derived either from Vibrio cholerae (VCN) or Clostridium perfringens (CPN) lost their i.p. transplantability for normal DBA/2 mice. This loss of transplantability could not be observed when the enzyme treated cells were implanted in mice whose immune status was suppressed by prior cyclophosphamide treatment. Mice receiving i.p. implants of enzyme treated leukaemia cells developed immunity to subsequent i.p. challenge with untreated L 1210 cells but not to a challenge with Ehrlich ascites tumour cells. The magnitude of immune response evoked by L 1210 cells preincubated with 250 u/ml of VCN or 35 μg/ml of CPN for 60 minutes was of relatively low level when compared with the immunity induced by leukaemia cells preincubated with 50 u/ml of VCN or 15 μg/ml of CPN for 30 or 60 minutes. Evidence is presented to show that the induced immunity can be transferred passively with the serum and with the peritoneal cells from the mice implanted with VCN treated L 1210 cells to normal DBA/2 mice. The significance of the neuraminidase induced increase in the immunogenicity of treated tumour cells is discussed.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4348470      PMCID: PMC2008844          DOI: 10.1038/bjc.1973.14

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  15 in total

1.  Experimental evaluation of potential anticancer agents. XXI. Scheduling of arabinosylcytosine to take advantage of its S-phase specificity against leukemia cells.

Authors:  H E Skipper; F M Schabel; W S Wilcox
Journal:  Cancer Chemother Rep       Date:  1967-06

2.  Complement sensitivity of neuraminidase-treated lymphoid cells.

Authors:  P K Ray; H Gewurz; R L Simmons
Journal:  Transplantation       Date:  1971-10       Impact factor: 4.939

3.  Combined effects of chemotherapy and immunity against leukemia L1210 in DBA-2 mice.

Authors:  E Mihich
Journal:  Cancer Res       Date:  1969-04       Impact factor: 12.701

4.  Immunogenicity of L 1210 murine leukaemia cells after treatment with neuraminidase.

Authors:  K D Bagshawe; G A Currie
Journal:  Nature       Date:  1968-06-29       Impact factor: 49.962

5.  Effect of enzymatic removal of cell surface sialic acid on the adherence of Walker 256 tumor cells to mesothelial membrane.

Authors:  D Cormack
Journal:  Cancer Res       Date:  1970-05       Impact factor: 12.701

6.  An alteration in tumor histocompatibility induced by neuraminidase.

Authors:  B H Sanford
Journal:  Transplantation       Date:  1967-09-05       Impact factor: 4.939

7.  Screening data from the Cancer Chemotherapy National Service Center Screening Laboratories. XXI.

Authors:  J Leiter; B J Abbott; S A Schepartz
Journal:  Can Res Suppl       Date:  1964-12

8.  Tumour specific immunogenicity of methylcholanthrene-induced sarcoma cells after incubation in neuraminidase.

Authors:  G A Currie; K D Bagshawe
Journal:  Br J Cancer       Date:  1969-03       Impact factor: 7.640

9.  The effect of neuraminidase on the fate of transfused lymphocytes.

Authors:  J J Woodruff; B M Gesner
Journal:  J Exp Med       Date:  1969-03-01       Impact factor: 14.307

10.  The role of sialic acid in antigenic expression: further studies of the Landschütz ascites tumour.

Authors:  G A Currie; K D Bagshawe
Journal:  Br J Cancer       Date:  1968-12       Impact factor: 7.640

View more
  6 in total

1.  Antitumor immune response following injection of neuraminidase-treated sarcoma cells.

Authors:  R P Faraci; J A Marrone; A S Ketcham
Journal:  Ann Surg       Date:  1975-03       Impact factor: 12.969

2.  Reappearance in vivo of neuraminidase-sensitive sialic acid in L 5222 rat leukemia cells.

Authors:  C Roeder; G Haemmerli; P Sträuli
Journal:  Experientia       Date:  1976-08-15

3.  Tumor therapy of neoplastic diseases with tumor cells and neuraminidase. Further experimental studies on chessboard vaccination in canine mammary tumors.

Authors:  H H Sedlacek; G Hagmayer; F R Seiler
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

Review 4.  Chemical xenogenization of experimental tumors.

Authors:  P Puccetti; L Romani; M C Fioretti
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

5.  Effect of levamisole on cytotoxic T-cell-mediated immune resistance to L1210 murine leukemia in hyperimmune mice.

Authors:  K Gomi; M Morimoto; T Kataoka
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

6.  Neuraminidase and tumor immunotherapy.

Authors:  H H Sedlacek; F R Seiler; H G Schwick
Journal:  Klin Wochenschr       Date:  1977-03-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.